Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Download PDF Copy

Dec 22 2014

NewsGuard 100/100 Score

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN^® for the treatment of pancreatic and ovarian cancers.

"This is the second jurisdiction in which we have elected to file for Orphan Designation," said Dr. Brad Thompson, President and CEO of Oncolytics. "The EMA serves all 28 member countries of the EU and securing Orphan Designation would help support the future development of REOLYSIN^® in the region."

Source:

Oncolytics Biotech Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: Biotechnology, Cancer, Ovarian Cancer, Pancreatic Cancer

Comments (0)

Download PDF Copy

Suggested Reading

Study reveals how cancer cells evade chemotherapy in low-glucose environments

Study reveals how cancer cells evade chemotherapy in low-glucose environments

Golgi apparatus plays crucial role in enhancing T-cell function against cancer

Golgi apparatus plays crucial role in enhancing T-cell function against cancer

Stanford team uses natural cell death mechanism to kill cancer cells

Stanford team uses natural cell death mechanism to kill cancer cells

Revolutionary strategy offers hope for type 1 diabetes treatment

Revolutionary strategy offers hope for type 1 diabetes treatment

MR1 molecule and vitamin B6 could unlock new paths for cancer immunotherapy

MR1 molecule and vitamin B6 could unlock new paths for cancer immunotherapy

Mursla Bio announces promising results for EvoLiver test in liver cancer detection

Mursla Bio announces promising results for EvoLiver test in liver cancer detection

Nanoparticle coating enhances cancer drug delivery and reduces side effects

Nanoparticle coating enhances cancer drug delivery and reduces side effects

History of endometriosis and fibroids linked to higher long-term risk of early death

History of endometriosis and fibroids linked to higher long-term risk of early death

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Rare genetic mutations in healthy women may be key to breast cancer origins